1-5 of 5
Margarete Stampfl
Close
Sort by
Journal Articles

Cox Proportional Hazards Deep Neural Network Identifies Peripheral Blood Complete Remission (PB-CR) to be at Least Equivalent to Morphologic CR in Predicting Outcomes of Patients Treated with Azacitidine - a Prospective Cohort Study By the AGMT

Lisa Pleyer, Marc Vaisband, Michael Pfeilstocker, Reinhard Stauder, Sonja Heibl, Heinz Sill, Michael Girschikofsky, Margarete Stampfl-Mattersberger, Christoph Tinchon, Bernd L. Hartmann, Andreas Petzer, Martin Schreder, Clemens A. Schmitt, Sonia Vallet, Thomas Melchardt, Lukas Scagnetti, Armin Zebisch, Sigrid Machherndl-Spandl, Dominik Wolf, Felix Keil, Jan Hasenauer, Richard Greil
Journal: Blood
Blood (2022) 140 (Supplement 1): 1346–1349.
https://doi.org/10.1182/blood-2022-168521
Published: 2022
Journal Articles

Peripheral Blood Complete Remission Provides Added Value to the Classical Definition of Morphologic Complete Remission - a Prospective Cohort Study of 1441 Patients with MDS, CMML and AML Treated within the Austrian Azacitidine Registry

Lisa Pleyer, Michael Pfeilstocker, Reinhard Stauder, Sonja Heibl, Heinz Sill, Michael Girschikofsky, Margarete Stampfl-Mattesberger, Christoph Tinchon, Bernd Hartmann, Andreas Petzer, Branka Petricevic, Clemens A. Schmitt, Sonja Vallet, Klaus Geissler, Wolfgang R. Sperr, Michael Leisch, Alexander Egle, Thomas Melchardt, Gudrun Piringer, Armin Zebisch, Sigrid Machherndl-Spandl, Dominik Wolf, Felix Keil, Hubert Angermann, Manuel Drost, Julian Larcher-Senn, Richard Greil
Journal: Blood
Blood (2021) 138 (Supplement 1): 3387.
https://doi.org/10.1182/blood-2021-145401
Published: 2021
Journal Articles

Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group

Lisa Pleyer, Michael Pfeilstocker, MD, Reinhard Stauder, MD MSc, Sonja Heibl, MD, Heinz Sill, MD, Michael Girschikofsky, MD, Margarete Stampfl-Mattersberger, MD, Christoph Tinchon, MD, Andreas Petzer, MD, Clemens A. Schmitt, MD, Sonia Vallet, MD, Inga Mandac, MD, Klaus Geissler, MD, Wolfgang R. Sperr, MD, Michael Leisch, MD, Alexander Egle, MD, Thomas Melchardt, MD PhD, Julia Fusinato, BSc, Gudrun Piringer, MD MSc, Armin Zebisch, MD, Sigrid Machherndl-Spandl, MD, Dominik Wolf, MD, Felix Keil, MD, Richard Greil, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3821.
https://doi.org/10.1182/blood-2019-128153
Published: 2019
Journal Articles

Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study Results

Heinz Gisslinger, Veronika Buxhofer-Ausch, MD, Josef Thaler, MD, Ernst Forjan, MD, Ella Willenbacher, MD, Dominik Wolf, MD, Robert Kralovics, PhD, Bettina Gisslinger, Margarete Stampfl-Mattersberger, Alexander Egle, MD, Thomas Melchardt, MD, Sonja Burgstaller, MD, Martin Schalling, MSc, Maria-Theresa Krauth, MD, Richard Greil, MD, Pavla Kadlecova, Michael Zoerer, Victoria Empson, MSc, Barbara Grohmann-Izay, MD MSc, Christoph Klade, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3030.
https://doi.org/10.1182/blood-2018-99-118584
Published: 2018
Journal Articles

Combination Therapy with Lenalidomide, Bortezomib, Liposomal Doxorubicin and Dexamethasone (LBlipDD) May Overcome Resistance to Prior Treatment with Doxorubicin, Lenalidomide, and Bortezomib in High-Risk Multiple Myeloma (MM).

Reinhard Ruckser, Georg Tatzreiter, Elvira Kitzweger, Karin Strecker, Stefan Hraby, Veronika Buxhofer, Margarete Stampfl, Peter Kier, Karl H. Habertheuer, Milos Hejtman, Wolfgang Hinterberger
Journal: Blood
Blood (2007) 110 (11): 4838.
https://doi.org/10.1182/blood.V110.11.4838.4838
Published: 2007